Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Hodge Website

James W. Hodge, Ph.D., MBA

Selected Publications

1)  Donahue RN, Duncan BB, Fry TJ, Jones B, Bachovchin WW, Kiritsy CP, Lai JH, Wu W, Zhao P, Liu Y, Tsang KY, Hodge JW.
A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines.
Vaccine. 2014.
[Journal]
2)  Wattenberg MM, Kwilas AR, Gameiro SR, Dicker AP, Hodge JW.
Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets.
Br. J. Cancer. 110: 1472-80, 2014.
[Journal]
3)  Campbell CT, Gulley JL, Oyelaran O, Hodge JW, Schlom J, Gildersleeve JC.
Humoral response to a viral glycan correlates with survival on PROSTVAC-VF.
Proc. Natl. Acad. Sci. U.S.A. 2014.
[Journal]
4)  Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW.
Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing.
Oncotarget. 5: 403-16, 2014.
[Journal]
5)  Bernstein MB, Garnett CT, Zhang H, Velcich A, Wattenberg MM, Gameiro SR, Kalnicki S, Hodge JW, Guha C.
Radiation-Induced Modulation of Costimulatory and Coinhibitory T-Cell Signaling Molecules on Human Prostate Carcinoma Cells Promotes Productive Antitumor Immune Interactions.
Cancer Biother. Radiopharm. 2014.
[Journal]
6)  Ardiani A, Gameiro SR, Palena C, Hamilton DH, Kwilas A, King TH, Schlom J, Hodge JW.
Vaccine-Mediated Immunotherapy Directed against a Transcription Factor Driving the Metastatic Process.
Cancer Res. 2014.
[Journal]
7)  Huang J, Jochems C, Anderson AA, Talaie T, Jales A, Madan RA, Hodge JW, Tsang KY, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J.
Soluble CD27-pool in humans may contribute to T-cell activation and tumor immunity.
J Immunol. 2013.
In Press. [Journal]
8)  Singh N, Hodge JW, Madan R, Gulley JL.
Shurin MR, Umansky V, Malyguine A, eds.
Combining vaccines with therapies that render tumor cells more susceptible to immune mediated killing. In: The Tumor Immunoenvironment.
Dordrecht: Springer Science+Business Media; 2013. p. 621-642 [Book Chapter]
9)  Hodge JW, Kwilas A, Ardiani A, Gameiro SR.
Attacking malignant cells that survive therapy: Exploiting immunogenic modulation.
Oncoimmunology. 2: e26937, 2013.
[Journal]
10)  Gameiro SR, Jammeh ML, Hodge JW.
Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise.
Expert Rev Vaccines. 12: 617-29, 2013.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 4/17/2014.